Seagen (Nasdaq:SGEN) - Hisse Senedi Fiyatı, Haberler ve Analizler

SGEN Stoklara Genel Bakış

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. Daha fazla detay

SGEN temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	6/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Kazançların yılda 71.8% oranında artması öngörülüyor

Risk Analizi

Risk kontrollerimizden SGEN için herhangi bir risk tespit edilmedi.

Seagen Inc. Rakipler

Biogen

NasdaqGS:BIIB

US$22.7b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$80.0b

Gilead Sciences

NasdaqGS:GILD

US$110.5b

Horizon Therapeutics

NasdaqGS:HZNP

US$26.6b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Seagen
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$228.74
52 Haftanın En Yüksek Seviyesi	US$228.96
52 Haftanın En Düşük Seviyesi	US$123.77
Beta	0.32
11 Aylık Değişim	7.86%
3 Aylık Değişim	9.76%
1 Yıllık Değişim	76.48%
33 Yıllık Değişim	13.72%
5 Yıllık Değişim	336.44%
Halka arzdan bu yana değişim	2,672.61%

Son Haberler & Güncellemeler

Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Dec 12

Recent updates

Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Dec 12

A Look At The Fair Value Of Seagen Inc. (NASDAQ:SGEN)

Apr 17

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Mar 20

An Intrinsic Calculation For Seagen Inc. (NASDAQ:SGEN) Suggests It's 47% Undervalued

Dec 09

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Oct 14

Hissedar Getirileri

	SGEN	US Biotechs	US Pazar
7D	4.5%	-6.5%	-1.0%
1Y	76.5%	14.6%	30.3%

Getiri vs. Endüstri: SGEN geçen yıl % 14.6 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: SGEN geçen yıl % 30.3 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is SGEN's price volatile compared to industry and market?
SGEN volatility
SGEN Average Weekly Movement	1.8%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: SGEN son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: SGEN 'nin haftalık oynaklığı ( 2% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1997	3,256	David Epstein	www.seagen.com

Seagen Inc. Temel Bilgiler Özeti

Seagen'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
SGEN temel i̇stati̇sti̇kler
Piyasa değeri	US$43.15b
Kazançlar(TTM)	-US$750.22m
Gelir(TTM)	US$2.30b

18.8x

P/S Oranı

-57.5x

F/K Oranı

SGEN aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
SGEN gelir tablosu (TTM)
Gelir	US$2.30b
Gelir Maliyeti	US$2.13b
Brüt Kâr	US$171.59m
Diğer Giderler	US$921.81m
Kazançlar	-US$750.22m

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.98
Brüt Marj	7.46%
Net Kâr Marjı	-32.61%
Borç/Özkaynak Oranı	0%

SGEN uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

SGEN Stoklara Genel Bakış

Ödüller

Risk Analizi

Seagen Inc. Rakipler

NasdaqGS:BIIB

US$22.7b

NasdaqGS:REGN

US$80.0b

NasdaqGS:GILD

US$110.5b

NasdaqGS:HZNP

US$26.6b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Seagen Inc. Files Form 15

Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD)

Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.

Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine

Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA

Recent updates

Seagen Inc. Files Form 15

Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD)

Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.

Seagen Inc.'s (NASDAQ:SGEN) Popularity With Investors Is Under Threat From Overpricing

Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine

Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Chief Technical Officer notifies of intention to sell stock

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Seagen Inc. Announces to Highlight Overall Survival Data for Padcev and Tivdak During Presidential Symposium At Esmo Congress 2023

Seagen Inc. to Report Q3, 2023 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Chief Technical Officer notifies of intention to sell stock

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Insider notifies of intention to sell stock

Seagen Inc. Announces Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA®? (tucatinib) in Combination with Antibody-Drug Conjugate Ado-Trastuzumab Emtansine

Consensus EPS estimates fall by 12%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Seagen Inc. to Report Q2, 2023 Results on Aug 02, 2023

Seagen Inc. Announces Phase 3 Trial of Adcetris (Brentuximab Vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% Vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL)

Chief Technical Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

First quarter 2023 earnings: EPS misses analyst expectations

Price target increased by 7.3% to US$216

Insider notifies of intention to sell stock

A Look At The Fair Value Of Seagen Inc. (NASDAQ:SGEN)

Chief Financial Officer exercised options and sold US$8.8m worth of stock

Independent Director notifies of intention to sell stock

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation

Price target increased by 7.7% to US$181

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Consensus EPS estimates fall by 22%

Independent Director exercised options to buy US$1.4m worth of stock.

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President of Research & Development notifies of intention to sell stock

President of Research & Development notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023

President of Research & Development notifies of intention to sell stock

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Independent Director exercised options to buy US$1.1m worth of stock.

Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

An Intrinsic Calculation For Seagen Inc. (NASDAQ:SGEN) Suggests It's 47% Undervalued

Price target decreased to US$166

Chief Legal Officer exercised options to buy US$171k worth of stock.

Independent Director recently sold US$968k worth of stock

Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Price target decreased to US$169

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Chief Medical Officer & Interim CEO notifies of intention to sell stock

Here's Why We're Not At All Concerned With Seagen's (NASDAQ:SGEN) Cash Burn Situation